Sign inJoin waitlistJoin the waitlist

Duncan Stearns

Associate Professor, CWRU School of Medicine · Case Western Reserve University/University Hospitals Cleveland Medical Center

Credentials: · · · · ·

History

Johns Hopkins Hospital
2003–2005
Pediatric Hematology Oncology
Johns Hopkins Hospital
2000–2003
Pediatrics
Rhode Island Hospital/Brown University Health
1997–2000
University of Pittsburgh School of Medicine
1993–1997
Harvard University
1983–1987

Research

Comprehensive Analysis of Hypermutation in Human Cancer
Cell · 2017 · 636 citations
Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors
Cancer Research · 2006 · 482 citations
Alex's Lemonade Stand Foundation Infant and Childhood Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011
Neuro-Oncology · 2015 · 437 citations

CE
Charles Eberhart
11 papers · 2 as a fellow
Scott Lindhorst
4 papers
VR
Vijay Ramaswamy
4 papers
AB
Anne Bendel
3 papers
Daniel Bowers
3 papers
GT
Gregory Thomas
3 papers
KC
Kenneth Cohen
3 papers
Kristina Cole
3 papers
Peter de Blank
3 papers
Phillip Storm
3 papers
Alex Huang
2 papers
Alyssa Reddy
2 papers

Clinical trials

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
Site PI · Recruiting · Phase 3
Children's Oncology Group
2026–2033
Quality of End-of-Life Care for Children With Cancer
Site PI · Recruiting
Children's Oncology Group
2026–2031
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2028
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2030